Condition: Anatomic Stage II Breast Cancer AJCC v8 · Early Stage Triple-Negative Breast Carcinoma · Anatomic Stage IIIA Breast Cancer AJCC v8 · Sponsor: Alliance for Clinical Trials in Oncology
This phase III trial compares the effect of continuation of treatment with pembrolizumab (usual approach) to observation only at preventing cancer from coming back in patients with early-stage triple-negative breast cancer (TNBC) who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. The usual approach for patients with early-stage TNBC who receive preoperative chemotherapy plus pembrolizumab is to continue to receive pembrolizumab for up to 27 weeks after surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation is as good as receiving pembrolizumab for 27 weeks after surgery in triple-negative breast cancer patients who achieved a pathologic complete response after preoperative treatment with chemotherapy and pembrolizumab.
This description comes directly from the study's public registry record.
Sara Tolaney, MD · 617-632-2335 · Sara_Tolaney@dfci.harvard.edu
Laura Hoffman · 773-834-2546 · lhoffman22@bsd.uchicago.edu
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham Cancer Center | Birmingham, Alabama, United States | Active Not Recruiting |
| Thomas Hospital | Fairhope, Alabama, United States | Recruiting |
| Mobile Infirmary Medical Center | Mobile, Alabama, United States | Recruiting |
| University of South Alabama Mitchell Cancer Institute | Mobile, Alabama, United States | Recruiting |
| Katmai Oncology Group | Anchorage, Alaska, United States | Recruiting |
| CTCA at Western Regional Medical Center | Goodyear, Arizona, United States | Recruiting |
| Kingman Regional Medical Center | Kingman, Arizona, United States | Recruiting |
| Cancer Center at Saint Joseph's | Phoenix, Arizona, United States | Recruiting |
| Mayo Clinic Hospital in Arizona | Phoenix, Arizona, United States | Recruiting |
| Highlands Oncology Group - Fayetteville | Fayetteville, Arkansas, United States | Recruiting |
| NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro | Jonesboro, Arkansas, United States | Recruiting |
| University of Arkansas for Medical Sciences | Little Rock, Arkansas, United States | Recruiting |
+ 830 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05812807